Pioneering the Future of Natural Health: A Strengthened Collaboration Between Sibelius and the University of Buckingham

At Sibelius, our mission has always been to unlock the potential of natural products to enhance healthspan and wellbeing. We are excited to announce a significant step forward in this mission with the signing of a Memorandum of Understanding with the University of Buckingham’s Clore Laboratory for Biomedical Research. This agreement extends our long-term collaboration and establishes a dedicated Research/Working Group focused on the development of bioactive molecules from medicinal plants with a particular focus on supporting metabolic health.

Addressing "Diabesity" with Plant-Based Alternatives

The prevalence of metabolic diseases, particularly obesity and type 2 diabetes, continues to rise globally. While there are numerous synthetic anti-obesity and anti-diabetes drugs available, they often come with a range of adverse side effects, including cardiovascular issues, gastrointestinal problems, hepatotoxicity, and more. This makes the need for safer, more effective alternatives ever more pressing.

Our collaboration aims to meet this demand by exploring plant-based alternatives. By identifying and developing bioactive compounds from medicinal plants, we hope to provide safe and efficient nutraceuticals. This initiative will specifically target early interventions to maintain health through the management of bodyweight gain and maintenance of insulin sensitivity, crucial factors in combating “diabesity.”

About the Clore Laboratory for Biomedical Research

The Clore Laboratory at the University of Buckingham is internationally recognised for its expertise in metabolic diseases, inflammation, and oxidative stress-related conditions. With over 200 peer-reviewed publications and a track record in drug discovery, the laboratory brings invaluable knowledge and experience to our partnership. Their research encompasses basic science, drug discovery, and pre-clinical studies, with a particular focus on natural products for diabetes and bodyweight management. Their efforts to translate key research themes into clinical applications align perfectly with our goals at Sibelius.

Sibelius' Commitment to Innovation

At Sibelius, we are dedicated to increasing healthspan and wellbeing through the development of scientifically evidenced and clinically proven natural ingredients. Our patented Chronoscreen™ platform plays a pivotal role in this process, enabling us to screen natural products for robust biological activity and develop them into high-quality dietary supplements.

Following the success of Sibelius™:Sage , an extract of sage (Salvia officinalis) known for its cognitive performance benefits in older adults, we are excited to develop the next generation of ingredients in our portfolio. This collaboration with the University of Buckingham represents a significant milestone in our journey, promising innovative, natural solutions for today's health challenges.